Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence ...

Explore insights on Recursion Pharmaceuticals' pipeline as mixed clinical data and upcoming 2025 studies shape its future potential.

Recursion’s collaboration within Neuroscience and a GI Oncology indication for Roche and Genentech continues to bring unbiased novel biological insights to potential programs.

Recursion acquires full interest in Rallybio's ENPP1 inhibitor program to develop a potential oral treatment for hypophosphatasia.

All told, Recursion is “deprioritizing” three clinical-stage programs, pausing another and winding down a single preclinical program in an undisclosed target, the company revealed in its first ...

How to write a Java palindrome program for Strings Good programmers need to create code that efficiently solves problems, using various methods. A popular academic exercise is to create a program that ...

Recursion Pharmaceuticals ( (RXRX)) just unveiled an announcement. On July 8, 2025, Recursion Pharmaceuticals acquired full ownership of the ENPP1 inhibitor program, REV102, from Rallybio, aiming ...

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...

SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...